SuperworthPDS Biotechnology market cap PDSB
Share price times shares outstanding: what the whole company sells for, since 2015.
- Today, Oct 23, 2026
- $62.1M
- Highest close in our data
- $531M
- Mar 2018
PDS Biotechnology is worth $62.1M at the close on Oct 23, 2026, at $1.11 a share.
That is up 45% over the last year and down 82% over five years.
Its highest close in our data was $531M in Mar 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $62.1M | $11.8M | $77.2M | +40% |
| 2025 | $44.3M | $37M | $80M | −31% |
| 2024 | $64M | $61.7M | $205M | −59% |
| 2023 | $154.6M | $124.1M | $324.4M | −59% |
| 2022 | $376.3M | $84.5M | $376.3M | +63% |
| 2021 | $230.3M | $53.2M | $470.7M | +383% |
| 2020 | $47.6M | $3.9M | $60.4M | +178% |
| 2019 | $17.2M | $8.9M | $37.3M | +69% |
| 2018 | $10.2M | $10.2M | $531M | −96% |
| 2017 | $289.2M | $226.6M | $363.8M | −20% |
| 2016 | $361.5M | $190.4M | $370.2M | +0% |
| 2015 | $360.1M | $360.1M | $485.2M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest PDS Biotechnology's size, closest first, today.
| Company | Market cap |
|---|---|
| PDSBPDS Biotechnology | $62.1M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| ATNMActinium Pharmaceuticals | $47.8M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| Peer median | $477.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on PDS Biotechnology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.